Articles with public access mandates - Carol MorenoLearn more
Not available anywhere: 5
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
JG Gribben, F Bosch, F Cymbalista, CH Geisler, P Ghia, P Hillmen, ...
British journal of haematology 180 (5), 666-679, 2018
Mandates: US National Institutes of Health, Cancer Research UK, Wellcome Trust
MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia
G Ferrer, A Navarro, K Hodgson, M Aymerich, A Pereira, T Baumann, ...
Leukemia & lymphoma 54 (9), 2016-2022, 2013
Mandates: Government of Spain
Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status
K Hatzi, R Catera, CM Atanasio, VA Fischetti, SL Allen, JE Kolitz, KR Rai, ...
Clinical Immunology 172, 44-51, 2016
Mandates: US National Institutes of Health
Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy
EP Vicente, C Cuellar-García, M Martinez, A Soler, A Mora, R Bosch, ...
Clinical Lymphoma, Myeloma and Leukemia 18 (11), 737-742, 2018
Mandates: Banking Foundation "la Caixa", Government of Spain
Chronic lymphocytic leukemia chemotherapy: two decades of progress
C Moreno, E Montserrat
Future Medicine Ltd, 2012
Mandates: Government of Spain
Available somewhere: 24
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
Mandates: US National Institutes of Health
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European …
AC Rawstron, C Fazi, A Agathangelidis, N Villamor, R Letestu, ...
Leukemia 30 (4), 929, 2016
Mandates: US National Institutes of Health
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
JR Brown, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, SE Coutre, ...
Leukemia 32 (1), 83, 2018
Mandates: US National Institutes of Health
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ...
Blood 126 (16), 1921-1924, 2015
Mandates: Cancer Research UK, National Institute for Health Research, UK, Fondazione …
Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
JC Byrd, P Hillmen, S O'Brien, JC Barrientos, NM Reddy, S Coutre, ...
Blood, blood-2018-08-870238, 2019
Mandates: US National Institutes of Health
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, ...
Leukemia, 1, 2018
Mandates: German Research Foundation, Swedish Research Council, European Commission
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring …
AC Rawstron, S Böttcher, R Letestu, N Villamor, C Fazi, H Kartsios, ...
Leukemia 27 (1), 142, 2013
Mandates: Fondazione Cariplo
In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia
C Calissano, RN Damle, G Hayes, EJ Murphy, MK Hellerstein, C Moreno, ...
Blood 114 (23), 4832-4842, 2009
Mandates: US National Institutes of Health
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence
N Darzentas, A Hadzidimitriou, F Murray, K Hatzi, P Josefsson, ...
Leukemia 24 (1), 125, 2010
Mandates: Swedish Research Council
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
PM Barr, T Robak, C Owen, A Tedeschi, O Bairey, NL Bartlett, JA Burger, ...
haematologica 103 (9), 1502-1510, 2018
Mandates: US National Institutes of Health
Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American …
MA Kharfan-Dabaja, A Kumar, M Hamadani, S Stilgenbauer, P Ghia, ...
Biology of Blood and Marrow Transplantation 22 (12), 2117-2125, 2016
Mandates: US National Institutes of Health
Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment
K Hodgson, G Ferrer, A Pereira, C Moreno, E Montserrat
British journal of haematology 154 (1), 14-22, 2011
Mandates: Government of Spain
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
AS Michallet, M Aktan, W Hiddemann, O Ilhan, P Johansson, K Laribi, ...
haematologica 103 (4), 698-706, 2018
Mandates: National Institute for Health Research, UK
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
A Puiggros, R Collado, MJ Calasanz, M Ortega, N Ruiz-Xivillé, ...
Oncotarget 8 (33), 54297, 2017
Mandates: Government of Spain
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells
T Seiler, M Woelfle, S Yancopoulos, R Catera, W Li, K Hatzi, C Moreno, ...
Blood 114 (17), 3615-3624, 2009
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program